376 related articles for article (PubMed ID: 38136311)
1. Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies.
Olejarz W; Basak G
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136311
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.
Wang S; Zhao X; Wu S; Cui D; Xu Z
Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
Chyuan IT; Chu CL; Hsu PN
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
9. CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq MH; Al-Haideri M; Mohammad TAM; Gharebakhshi F; Marofi F; Tahmasebi S; Modaresahmadi S
Med Oncol; 2023 Apr; 40(5):155. PubMed ID: 37083979
[TBL] [Abstract][Full Text] [Related]
10. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
11. Emerging Novel Combined CAR-T Cell Therapies.
Nguyen A; Johanning G; Shi Y
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326556
[TBL] [Abstract][Full Text] [Related]
12. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma.
Liang T; Song Y; Gu L; Wang Y; Ma W
Int J Gen Med; 2023; 16():4121-4141. PubMed ID: 37720174
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
Nogami A; Sasaki K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
15. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
16. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
17. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies.
Shah NN; Maatman T; Hari P; Johnson B
Front Oncol; 2019; 9():146. PubMed ID: 30915277
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
19. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
20. The emerging role for CAR T cells in solid tumor oncology.
Klobuch S; Seijkens TTP; Haanen JBAG
Chin Clin Oncol; 2023 Apr; 12(2):19. PubMed ID: 37160670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]